Drug intelligence / Profile preview

EDO-1-127

Development stage: Preclinical
Lead developer: Georgetown University
Modality: Small Molecules
Administration: Oral

Overview

EDO-1-127 is a small molecule BRCA1-mimetic and an analog of 2,6-dibenzyl-5-phenylpyrimidin-4-amine (A9). Developed by researchers at Georgetown University, EDO-1-127 is designed to inhibit estrogen receptor alpha (ER-1/ESR1) activity, mimicking the tumor suppressor function of BRCA1. In preclinical studies, it has demonstrated potent inhibition of estrogen-stimulated estrogen response element (ERE)-luciferase activity, making it a potential therapeutic candidate for the treatment of breast cancer.

Other names: 2,6-bis(4-bromobenzyl)-5-(4-bromophenyl)pyrimidin-4-amine

Targets

ESR1 (ERα)

Beyond the preview

Go deeper on EDO-1-127.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDO-1-127.

Explore the full profile